David,
I treat many patients with ED in my practice and have been a fan of Muse since its release earlier this year (I've always been less impressed with Vivus' management style and marketing skills). I was, however, very impressed with the apparent sincerity of management's responses in today's CC.
Conceptually, the delivery system is first-rate and Muse, as a therapy for ED, it's VERY GOOD. As to be expected, patient selection, education and reasonable expectations are extremely important factors when evaluating this product's efficacy and patient satisfaction. Successful intercourse is certainly one objective endpoint, but it may not be the ONLY acceptable endpoint to a patient (take, for example, that unfortunate gentleman with severe cardiovascular disease who apparently died while using Muse. He was apparently a VERY happy customer).
I believe that the eventual release of Viagra will greatly benefit Vivus since so many people are now 'waiting in the wings' for this product and will be drawn into offices everwhere with high expectations. Certainly many will opt for an initial trial with 'the pill', but Muse will also be part of the armamentarium and possibly the ONLY option for many. Muse's future will be as a delivery system between the 'orals' and the 'injectables' with the hopeful transurethral administration of other exciting new vasodilatory agents such as forskolin, VIP, and possibly other specific PDE inhibitors. From a medical perspective, I believe the future is bright for Muse and Vivus.
Bradpalm1 |
